24.98

2.62% -0.61

Beam Therapeutics Inc (BEAM)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt BEAM? Forum Prognose

Schlusskurs vom Vortag:

$25.59

Offen:

$26

24-Stunden-Volumen:

745.12K

Relative Volume:

0.42

Marktkapitalisierung:

$2.54B

Einnahmen:

$139.74M

Nettoeinkommen (Verlust:

$-79.99M

KGV:

-24.59

EPS:

-1.0157

Netto-Cashflow:

$-360.05M

1W Leistung:

-6.10%

1M Leistung:

-10.74%

6M Leistung:

+20.97%

1J Leistung:

-0.56%

1-Tages-Spanne:

$24.75

$26.23

1-Wochen-Bereich:

$24.60

$27.92

52-Wochen-Spanne:

$13.53

$36.44

Beam Therapeutics Inc Stock (BEAM) Company Profile

Firmenname

Beam Therapeutics Inc

Sektor

Healthcare (1118)

Branche

Biotechnology (616)

Telefon

857-327-8775

Adresse

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Mitarbeiter

511

Twitter

Nächster Verdiensttermin

2024-11-05

Neueste SEC-Einreichungen

BEAM's Discussions on Twitter

Compare BEAM vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BEAM Beam Therapeutics Inc	24.92	2.61B	139.74M	-79.99M	-360.05M	-1.0157
VRTX Vertex Pharmaceuticals Inc	471.80	121.46B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	746.16	78.93B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	696.52	43.87B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	311.65	42.07B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.37	31.65B	5.36B	287.73M	924.18M	2.5229

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-02-20	Eingeleitet	Canaccord Genuity	Buy
2025-10-09	Eingeleitet	Jefferies	Buy
2025-03-28	Hochstufung	BofA Securities	Neutral → Buy
2025-03-10	Hochstufung	Scotiabank	Sector Perform → Sector Outperform
2025-01-29	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2024-11-06	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-10-16	Eingeleitet	Scotiabank	Sector Outperform
2024-07-23	Eingeleitet	H.C. Wainwright	Buy
2024-01-29	Hochstufung	JP Morgan	Neutral → Overweight
2023-12-15	Herabstufung	BofA Securities	Buy → Neutral
2023-12-08	Herabstufung	Jefferies	Buy → Hold
2023-10-20	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2023-10-20	Herabstufung	Leerink Partners	Outperform → Market Perform
2023-03-21	Eingeleitet	Bernstein	Mkt Perform
2023-02-01	Eingeleitet	Cantor Fitzgerald	Overweight
2022-12-20	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2022-12-13	Eingeleitet	Citigroup	Buy
2022-06-17	Eingeleitet	BMO Capital Markets	Market Perform
2022-04-28	Eingeleitet	Credit Suisse	Neutral
2022-01-05	Eingeleitet	Guggenheim	Buy
2021-10-19	Eingeleitet	SVB Leerink	Outperform
2021-09-24	Fortgesetzt	Stifel	Buy
2021-09-10	Eingeleitet	BofA Securities	Buy
2021-05-11	Eingeleitet	Redburn	Buy
2021-05-04	Eingeleitet	RBC Capital Mkts	Sector Perform
2021-03-01	Herabstufung	Barclays	Overweight → Equal Weight
2021-02-16	Eingeleitet	Wells Fargo	Overweight
2021-01-29	Herabstufung	JP Morgan	Overweight → Neutral
2021-01-06	Eingeleitet	Stifel	Hold
2020-08-05	Eingeleitet	William Blair	Outperform
2020-03-02	Eingeleitet	Barclays	Overweight
2020-03-02	Eingeleitet	JP Morgan	Overweight
2020-03-02	Eingeleitet	Jefferies	Buy
2020-03-02	Eingeleitet	Wedbush	Outperform

Alle ansehen

Beam Therapeutics Inc Aktie (BEAM) Neueste Nachrichten

Mar 12, 2026

Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It? - TradingView

Mar 12, 2026

Mar 06, 2026

Liquidity Mapping Around (BEAM) Price Events - Stock Traders Daily

Mar 06, 2026

Mar 05, 2026

According to a document submitted to the U.S. Securities and Exchange Commission (SEC) on March 2, Beam Therapeutics Inc. and Bio Palette have jointly decided to terminate the licensing agreement signed by both parties on March 27, 2019. - Bitget

Mar 05, 2026

Beam Therapeutics Restructures Base-Editing Licensing After Bio Palette Exit - TipRanks

Mar 05, 2026

Beam Therapeutics Inc. Terminates License Agreement with Bio Palette Co., Ltd - marketscreener.com

Mar 05, 2026

HC Wainwright Predicts Weaker Earnings for Beam Therapeutics - MarketBeat

Mar 05, 2026

JPMorgan Chase & Co. Trims Stock Position in Beam Therapeutics Inc. $BEAM - MarketBeat

Mar 05, 2026

ARK Investment Boosts Stake in Beam Therapeutics - National Today

Mar 05, 2026

Amova Asset Management Americas Inc. Buys 103,939 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat

Mar 05, 2026

ARK Investment Management LLC Increases Position in Beam Therapeutics Inc. $BEAM - MarketBeat

Mar 05, 2026

Mar 04, 2026

Beam Therapeutics Earnings Call Highlights PKU Pivot - TipRanks

Mar 04, 2026

What is HC Wainwright's Forecast for BEAM Q1 Earnings? - MarketBeat

Mar 04, 2026

Mar 03, 2026

Mintz Advises Sixth Street On $500 Million Strategic Financing Facility With Beam Therapeutics - Mondaq

Mar 03, 2026

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) - mx.advfn.com

Mar 03, 2026

H.C. Wainwright reiterates Beam Therapeutics stock rating at buy By Investing.com - Investing.com Australia

Mar 03, 2026

H.C. Wainwright reiterates Beam Therapeutics stock rating at buy - Investing.com Nigeria

Mar 03, 2026

Contrarius Group Holdings Ltd Buys Shares of 1,533,269 Beam Therapeutics Inc. $BEAM - MarketBeat

Mar 03, 2026

Mar 02, 2026

BEAM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 02, 2026

Vanguard Group Inc. Sells 455,440 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat

Mar 02, 2026

Feb 28, 2026

RBC Capital Maintains a Sector Perform Rating on Beam Therapeutics (BEAM), Here’s Why - Yahoo Finance

Feb 28, 2026

BEAM Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Feb 28, 2026

Feb 27, 2026

Should You Buy Beam Therapeutics Inc (BEAM) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI

Feb 27, 2026

Assessing Beam Therapeutics (BEAM) Valuation After Q4 Earnings Surprise Credit Facility And PKU Program Launch - simplywall.st

Feb 27, 2026

RBC Capital Maintains a Sector Perform Rating on Beam Therapeutics (BEAM), Here's Why - Bitget

Feb 27, 2026

Beam Therapeutics: Great Potential, But Patience Is Needed (NASDAQ:BEAM) - Seeking Alpha

Feb 27, 2026

Beam Therapeutics reveals new program for PKU - BioWorld MedTech

Feb 27, 2026

Feb 26, 2026

Bernstein SocGen cuts Beam Therapeutics stock price target on valuation By Investing.com - Investing.com Canada

Feb 26, 2026

Bernstein SocGen cuts Beam Therapeutics stock price target on valuation - Investing.com

Feb 26, 2026

Beam Therapeutics Clarifies Growth Path With PKU Program And New Financing - Yahoo Finance

Feb 26, 2026

Feb 25, 2026

Beam Therapeutics (BEAM) Quarterly Profit Surprises Loss Narrative With US$244.3 Million Net Income - simplywall.st

Feb 25, 2026

Beam Therapeutics (NASDAQ:BEAM) Trading Down 6.3%Time to Sell? - MarketBeat

Feb 25, 2026

Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street - WilmerHale

Feb 25, 2026

BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y - Finviz

Feb 25, 2026

Beam Therapeutics (NASDAQ:BEAM) Price Target Raised to $26.00 - MarketBeat

Feb 25, 2026

BEAM Shares See Target Price Boost by RBC Capital | BEAM Stock N - GuruFocus

Feb 25, 2026

Beam Therapeutics Stock Surges 14% on Strategic Financing: How the $500M Agreement Secures a $156 Target - TIKR.com

Feb 25, 2026

Beam Therapeutics Opens with 7.83% Gain, Outperforming S&P 500's 0.69% Rise - Markets Mojo

Feb 25, 2026

Beam Therapeutics Hits Day High with 17.04% Surge in Stock Price - Markets Mojo

Feb 25, 2026

Wedbush Raises BEAM Price Target to $65, Maintains Outperform Ra - GuruFocus

Feb 25, 2026

Beam Therapeutics (NASDAQ:BEAM) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat

Feb 25, 2026

Beam Therapeutics (BEAM) stock edges up premarket after 14% jump on results, $500 million facility - Bez Kabli

Feb 25, 2026

RBC Capital Adjusts Beam Therapeutics Price Target to $26 From $22, Maintains Sector PerformSpeculative Risk Rating - marketscreener.com

Feb 25, 2026

Beam Therapeutics Inc. (NASDAQ:BEAM) Q4 2025 Earnings Call Transcript - Insider Monkey

Feb 25, 2026

Mintz Advises Sixth Street on $500 Million Strategic Financing Facility with Beam Therapeutics - Mintz

Feb 25, 2026

Decoding Beam Therapeutics Inc (BEAM): A Strategic SWOT Insight - GuruFocus

Feb 25, 2026

Feb 24, 2026